Efficacy and safety of tacrolimus in patients with rheumatoid arthritis - A systematic review and meta-analysis. 2021

Yuko Kaneko, and Yutaka Kawahito, and Masayo Kojima, and Takeo Nakayama, and Shintaro Hirata, and Mitsumasa Kishimoto, and Hirahito Endo, and Yohei Seto, and Hiromu Ito, and Keiichiro Nishida, and Isao Matsushita, and Toshihisa Kojima, and Naoyuki Kamatani, and Kiichiro Tsutani, and Ataru Igarashi, and Mieko Hasegawa, and Nobuyuki Miyasaka, and Hisashi Yamanaka
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

OBJECTIVE To evaluate the efficacy and safety of tacrolimus in adult patients with rheumatoid arthritis (RA) by using the GRADE approach. METHODS We searched PubMed, Japana Centra Revuo Medicina Web (Ichu-shi web), and the Cochrane Database of Systematic Reviews. Articles fulfilling the predefined inclusion criteria were appraised and used for meta-analysis. The primary outcomes were American College of Rheumatology 20 (ACR20) and serum creatinine elevation. Other outcomes included ACR50, ACR70, changes in C-reactive protein, modified Health Assessment Questionnaire Disability Index, gastrointestinal disorders, metabolic and nutritional disorders, and infections and infestations. RESULTS We identified five randomized controlled studies, four of which compared tacrolimus to placebo and were included in the meta-analysis. The risk ratio of ACR20 achievement was 1.71 (95% confidence interval [CI] 1.20-2.42) for 1-2 mg/day and 2.30 (95% CI 1.79-2.96) for 3 mg/day. The risk ratio of creatinine elevation was 1.95 (95% CI 1.18-3.23) for 1-2 mg/day and 3.81 (95% CI 2.43-5.99) for 3 mg/day. CONCLUSIONS Tacrolimus is effective with acceptable safety in the management of RA.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D016559 Tacrolimus A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro. Anhydrous Tacrolimus,FK-506,FK506,FR-900506,Prograf,Prograft,Tacrolimus Anhydrous,Anhydrous, Tacrolimus,FK 506,FR 900506,FR900506,Tacrolimus, Anhydrous
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents

Related Publications

Yuko Kaneko, and Yutaka Kawahito, and Masayo Kojima, and Takeo Nakayama, and Shintaro Hirata, and Mitsumasa Kishimoto, and Hirahito Endo, and Yohei Seto, and Hiromu Ito, and Keiichiro Nishida, and Isao Matsushita, and Toshihisa Kojima, and Naoyuki Kamatani, and Kiichiro Tsutani, and Ataru Igarashi, and Mieko Hasegawa, and Nobuyuki Miyasaka, and Hisashi Yamanaka
October 2021, Clinical rheumatology,
Yuko Kaneko, and Yutaka Kawahito, and Masayo Kojima, and Takeo Nakayama, and Shintaro Hirata, and Mitsumasa Kishimoto, and Hirahito Endo, and Yohei Seto, and Hiromu Ito, and Keiichiro Nishida, and Isao Matsushita, and Toshihisa Kojima, and Naoyuki Kamatani, and Kiichiro Tsutani, and Ataru Igarashi, and Mieko Hasegawa, and Nobuyuki Miyasaka, and Hisashi Yamanaka
January 2021, Current rheumatology reviews,
Yuko Kaneko, and Yutaka Kawahito, and Masayo Kojima, and Takeo Nakayama, and Shintaro Hirata, and Mitsumasa Kishimoto, and Hirahito Endo, and Yohei Seto, and Hiromu Ito, and Keiichiro Nishida, and Isao Matsushita, and Toshihisa Kojima, and Naoyuki Kamatani, and Kiichiro Tsutani, and Ataru Igarashi, and Mieko Hasegawa, and Nobuyuki Miyasaka, and Hisashi Yamanaka
September 2023, Clinical and experimental rheumatology,
Yuko Kaneko, and Yutaka Kawahito, and Masayo Kojima, and Takeo Nakayama, and Shintaro Hirata, and Mitsumasa Kishimoto, and Hirahito Endo, and Yohei Seto, and Hiromu Ito, and Keiichiro Nishida, and Isao Matsushita, and Toshihisa Kojima, and Naoyuki Kamatani, and Kiichiro Tsutani, and Ataru Igarashi, and Mieko Hasegawa, and Nobuyuki Miyasaka, and Hisashi Yamanaka
June 2018, Experimental and therapeutic medicine,
Yuko Kaneko, and Yutaka Kawahito, and Masayo Kojima, and Takeo Nakayama, and Shintaro Hirata, and Mitsumasa Kishimoto, and Hirahito Endo, and Yohei Seto, and Hiromu Ito, and Keiichiro Nishida, and Isao Matsushita, and Toshihisa Kojima, and Naoyuki Kamatani, and Kiichiro Tsutani, and Ataru Igarashi, and Mieko Hasegawa, and Nobuyuki Miyasaka, and Hisashi Yamanaka
April 2023, European journal of internal medicine,
Yuko Kaneko, and Yutaka Kawahito, and Masayo Kojima, and Takeo Nakayama, and Shintaro Hirata, and Mitsumasa Kishimoto, and Hirahito Endo, and Yohei Seto, and Hiromu Ito, and Keiichiro Nishida, and Isao Matsushita, and Toshihisa Kojima, and Naoyuki Kamatani, and Kiichiro Tsutani, and Ataru Igarashi, and Mieko Hasegawa, and Nobuyuki Miyasaka, and Hisashi Yamanaka
January 2019, Frontiers in pharmacology,
Yuko Kaneko, and Yutaka Kawahito, and Masayo Kojima, and Takeo Nakayama, and Shintaro Hirata, and Mitsumasa Kishimoto, and Hirahito Endo, and Yohei Seto, and Hiromu Ito, and Keiichiro Nishida, and Isao Matsushita, and Toshihisa Kojima, and Naoyuki Kamatani, and Kiichiro Tsutani, and Ataru Igarashi, and Mieko Hasegawa, and Nobuyuki Miyasaka, and Hisashi Yamanaka
August 2018, Rheumatology international,
Yuko Kaneko, and Yutaka Kawahito, and Masayo Kojima, and Takeo Nakayama, and Shintaro Hirata, and Mitsumasa Kishimoto, and Hirahito Endo, and Yohei Seto, and Hiromu Ito, and Keiichiro Nishida, and Isao Matsushita, and Toshihisa Kojima, and Naoyuki Kamatani, and Kiichiro Tsutani, and Ataru Igarashi, and Mieko Hasegawa, and Nobuyuki Miyasaka, and Hisashi Yamanaka
March 2023, Heliyon,
Yuko Kaneko, and Yutaka Kawahito, and Masayo Kojima, and Takeo Nakayama, and Shintaro Hirata, and Mitsumasa Kishimoto, and Hirahito Endo, and Yohei Seto, and Hiromu Ito, and Keiichiro Nishida, and Isao Matsushita, and Toshihisa Kojima, and Naoyuki Kamatani, and Kiichiro Tsutani, and Ataru Igarashi, and Mieko Hasegawa, and Nobuyuki Miyasaka, and Hisashi Yamanaka
October 2010, Modern rheumatology,
Yuko Kaneko, and Yutaka Kawahito, and Masayo Kojima, and Takeo Nakayama, and Shintaro Hirata, and Mitsumasa Kishimoto, and Hirahito Endo, and Yohei Seto, and Hiromu Ito, and Keiichiro Nishida, and Isao Matsushita, and Toshihisa Kojima, and Naoyuki Kamatani, and Kiichiro Tsutani, and Ataru Igarashi, and Mieko Hasegawa, and Nobuyuki Miyasaka, and Hisashi Yamanaka
October 2013, BMC musculoskeletal disorders,
Copied contents to your clipboard!